Table 3.
Service delivery model components, by service type.
| # (%)* reporting, by type of service | iOAT | TiOAT | Safer Supply | Total | |
|---|---|---|---|---|---|
| Service delivery model/setting | Mar & May 1 (no change) | Mar & May 1 (no change) | Mar 1 | New as of May 1 | Combined |
| Comprehensive, dedicated iOAT clinic | 3 (16%) | 1 (33%) | 0 | 2 (3%) | 6 (6%) |
| Hospital-based | 2 (11%) | 0 | 2 (10%) | 1 (2%) | 5 (5%) |
| Pharmacy-based | 0 | 0 | 0 | 0 | 0 |
| Dedicated safer supply clinic | 0 | 0 | 1 (5%) | 0 | 1 (1%) |
| Prescriber's private practice | 0 | 0 | 4 (19%) | 5 (8%) | 9 (%) |
| Mobile outreach | 0 | 0 | 1 (5%) | 1 (2%) | 2 (2%) |
| COVID-19 isolation unit | 0 | 0 | 0 | 2 (3%) | 2 (2%) |
| Vending machine dispensing | 0 | 0 | 1 (5%) | 0 | 1 (1%) |
| Embedded in existing services | – | – | – | – | – |
| Housing | 5 (26%) | 0 | 3 (%) | 4 (7%) | 12 (12%) |
| Hospice | 1 (5%) | 0 | 1 (5%) | 0 | 2 (1%) |
| Shelter | 3 (16%) | 0 | 4 (19%) | 0 | 7 (7%) |
| Primary care clinic | 0 | 0 | 1 (5%) | 19 (32%) | 20 (%) |
| Community health centre | 4 (22%) | 0 | 5 (24%) | 3 (5%) | 12 (12%) |
| Addiction treatment program (e.g., oral OAT clinic) | 0 | 0 | 0 | 25 (42%) | 25 (19%) |
| Harm reduction program (e.g., overdose prevention/supervised consumption site) | 2 (11%) | 2 (67%) | 0 | 3 (5%) | 7 (7%) |
| Intensive case management team | 0 | 0 | 0 | 4 (7%) | 4 (4%) |
| Youth program | 0 | 0 | 0 | 2 (3%) | 2 (2%) |
| Mental health program | 0 | 0 | 0 | 7 (12%) | 7 (7%) |
| Perinatal clinic | 0 | 0 | 0 | 1 (2%) | 1 (1%) |
| Number reporting | 19/19(100%) | 3/3(100%) | 21/21 (100%) | 60/60 (100%) | 103/103(100%) |
| Pharmacy model | May 1 (no change from Mar 1 reported) | ||||
| # (%)* reporting, by type of service | iOAT | TiOAT | Safer Supply | Total | |
| Onsite pharmacy | 8 (44%) | 2 (67%) | 24 (55%) | 34 (52%) | |
| Hospital pharmacy partner | 2 (11%) | 0 | 4 (9%) | 6 (9%) | |
| Community pharmacy partner | 5 (28%) | 1 (33%) | 5 (11%) | 11 (17%) | |
| Informal relationship with some pharmacies | 0 | 0 | 1 (2%) | 1 (2%) | |
| Patient choice | 3 (17%) | 0 | 26 (59%) | 29 (45%) | |
| Delivery available | 5 (28%) | 0 | 15 (%) | 20 (31%) | |
| Number reporting | 18/19(95%) | 3/3(100%) | 44/81(54%) | 65/103(63%) | |
| Frequency seen by prescriber | May 1 (3 sites reported decreased frequency by May 1) | ||||
| # (%)* reporting, by type of service | iOAT | TiOAT | Safer Supply | Total | |
| Every 6 weeks or less | 0 | 0 | 4 (11%) | 4 (7%) | |
| Every 4 weeks | 0 | 2 (100%) | 21 (60%) | 23 (41%) | |
| Every 2 weeks | 0 | 1 (50%) | 16 (46%) | 18 (32%) | |
| Weekly | 0 | 0 | 21 (60%) | 21 (38%) | |
| More than once per week | 19 (100%) | 0 | 2 (6%) | 21 (38%) | |
| Number reporting | 19/19(100%) | 2/3(67%) | 35/81(43%) | 56/103(54%) | |
| Funding sources | May 1 (No change reported for Mar 1 sites) | ||||
| # (%)* reporting, by type of service | iOAT | TiOAT | Safer Supply | Total | |
| Federal government | 1 (5%) | 0 | 3 (4%) | 4 (4%) | |
| Provincial government Ministries | 9 (47%) | 0 | 0 | 9 (9%) | |
| Health authorities | 12 (63%) | 3 (100%) | 10 (12%) | 25 (24%) | |
| Community partners | 6 (32%) | 1 (33%) | 2 (2%) | 9 (9%) | |
| Private donations | 0 | 0 | 2 (2%) | 2 (2%) | |
| Patient fees | 0 | 0 | 2 (2%) | 2 (2%) | |
| No funding | 0 | 0 | 64 (79%) | 64 (62%) | |
| Number reporting | 19/19(100%) | 3/3(100%) | 81/81(100%) | 103/103 (100%) | |
Note: iOAT=injectable opioid agonist treatment; TiOAT=tablet-based iOAT; % add to more than 100% where more than one model was reported at a site; % represent only the proportion of those reporting.